MD1 Comparing Virtual Colonography with Conventional Colonoscopy for Colorectal Cancer Screening: What are the Drivers of Cost-effectiveness?  by Kriza, C. et al.
A328  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
large polyps, natural history of adenoma transition to cancer and importantly, 
adherence. CTC was found to be cost-effective in three studies, assuming the most 
favourable scenario. ConClusions: CTC has the potential to be a cost-effective 
CRC screening strategy when compared to COL. There is a strong need for a differ-
ential consideration of patient adherence and compliance to CTC and COL. Recent 
research shows that laxative-free CTC screening has the potential to become a viable 
alternative screening method for CRC as it can improve patient uptake of screening. 
This project is supported by the German Federal Ministry of Education and Research 
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objeCtives: With tightening health system budgets, medical devices (MDs) are 
being increasingly scrutinized for their impact on overall health care cost. The evi-
dence bar for implantable MDs is particular high since most implantable devices 
are not reimbursed separately by payers, but via direct bundled payments to the 
provider. To characterize that trend, the objectives of this study were to: 1) Identify 
specific evidence criteria that maximally impact the payer decision, 2) Note differ-
ences in HTAs across global markets, and finally 3) Outline differences in evidence 
requirements between drugs and devices. Methods: A multimarket review of 
implantable MD HTAs and reimbursement decisions published from 2008-2013 was 
conducted. Identified by HTA Watch, HTAs included those from Australia, Belgium, 
Canada, France, Germany, Italy, the UK and the US. They spanned a variety of indi-
cations, including cardiovascular, orthopedic, neurological, trauma, among others. 
HTAs and reimbursement decisions were characterized for clinical and economic 
evidence requirements and apparent correlations and/or impacts on ultimate 
agency recommendation. Results: Evidence criteria evaluated by HTA agencies 
and payers primarily included: 1) Availability of supportive randomized controlled 
trials (RCTs), 2) Safety, 3) Efficacy/long-term outcomes, 4) Cost/cost-offsets/budget 
impact, and 5) Quality of-life improvement. In contrast to drug HTAs, clinician 
training and learning curve effects were often evaluated. Importantly, agencies 
recognized the challenge in demonstrating statistically- and clinically-significant 
evidence of improvement in outcomes. As such, many MDs were recommended 
on a restricted basis to specific patient subpopulations or on a coverage based 
on continued evidence development. While requirements considered most critical 
were largely uniform across global markets, regional nuances impacted the ability 
to obtain favorable reimbursement of implantable devices. ConClusions: Similar 
to drugs, MDs face rising hurdles in terms of demonstrating value, both clinical and 
economic. Optimal global market access for implantable MDs hinges on monitoring 
evolving evidentiary requirements and on carefully planning to collect evidence 
early in the developmental cycle.
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objeCtives: Coverage with evidence development (CED) is increasingly being 
used to provide provisional coverage for promising, but unproven, interventions, 
while additional data are generated. This study aimed to explore the application of 
CED in the context of devices. Methods: First, a literature review was conducted 
on international CED schemes and the CED approach more generally. In total, 50 
articles were gathered and reviewed. Second, semi-structured telephone inter-
views were conducted with different expert groups (payers/HTA bodies, industry, 
and academics/policy analysts) to better understand the use of CED in different 
jurisdictions; identify and explore device CED case studies; and, gather expert 
opinion on the challenges associated with the CED approach and potential strate-
gies to improve current policy and practice. A total of 25 experts were invited to 
participate, of which 20 (80%) agreed and were interviewed. Results: Canada, 
the UK, and US have the most experience with CED applied to devices; Germany 
and The Netherlands have both recently introduced new CED policies for devices 
and procedures. Devices that have undergone CED in these jurisdictions include 
ICDs, stents, TAVI, laparoscopic surgery, and spinal cord stimulators. While there 
are distinct differences in the national approaches to CED, common challenges 
were identified: 1) establishing a clear framework for initiating, overseeing, and 
stopping CED studies, 2) identifying and applying appropriate study methods, 3) 
funding CED studies, 4) incentivizing studies, and 5) applying new evidence to 
inform coverage decisions. ConClusions: Devices are viable candidates for CED, 
given some of their unique characteristics and often uncertain evidence base at 
the time of coverage determination. However, improvements are needed, including 
enhanced clarity and predictability of CED selection criteria and processes, greater 
stakeholder collaboration, new models to fund studies and collect data, better 
incentives for physicians to engage in studies, and strengthened requirements 
for use of new evidence in coverage policies.
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objeCtives: During the last few years, there has been a steady increase in the 
number of implant registries, mainly in the field of arthroplasty. The benefit of a 
registry depends on its content and quality. However, there are no further data 
requirements, legal and financial issues or requirements for the organizational 
(p= 0.596). ConClusions: Time preference rates were aligned with those in the pub-
lished literature but the association between time preference and adherence was non-
significant in both primary and secondary analyses at an individual country level.
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objeCtives: Given economic pressure on UK National Health Service resources, it has 
been recommended that general practitioners prescribe more low-cost, generic drugs 
as opposed to high-cost, proprietary drugs when a substitution can be made without 
compromising patient care. One of the Better Care Better Value (BCBV) indicators of good 
prescribing practice proposed by the NHS Institute for Innovation and Improvement is 
an increase in the prescription of low-cost drugs for lipid modification. The objective of 
this analysis was to evaluate patterns of generic and proprietary prescribing of statins 
from 2007–2012 inclusive. Methods: Prescription Cost Analysis databases from data.
gov.uk were reviewed between 2007–2012. Data on the number of prescription items 
dispensed each year in the community in England for simvastatin and atorvastatin (as 
commonly-prescribed examples) were extracted, along with each drug’s preparation 
class: drugs prescribed and available generically, or drugs prescribed and dispensed by 
proprietary brand name. For both simvastatin and atorvastatin, the proportions of pre-
scription items in the different preparation classes were compared each year. Results: 
Proprietary simvastatin prescription items as a proportion of all simvastatin prescription 
items decreased each year, from 2.87% in 2007 (843,000 proprietary items) to 1.76% in 
2012 (752,000 items), representing a proportional decrease of 39% in the 6-year period 
assessed. Proprietary atorvastatin prescription items as a proportion of all atorvastatin 
prescription items were close to 100% between 2007–2011 (approximately 11 million 
proprietary items each year), but fell to 30.55% in 2012 (3.9 million items), coinciding 
with the expiry of atorvastatin’s patent in May 2012. ConClusions: In England, pre-
scribing of high-cost proprietary items for these two examples of lipid-modifying drugs 
has decreased since 2007, suggesting that the BCBV prescribing indicator for statins is 
being met. Such reductions, particularly as seen with atorvastatin in 2012, are likely to 
have a significant budget impact.
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objeCtives: Warfarin-treated patients with poor international normalized ratio 
(INR) control, measured with time in therapeutic range (TTR) or the standard 
deviation of transformed INR (SDTINR), have an increased risk for clinical events. 
To what extent only a short period with an altered INR control may influence out-
comes remains unknown. This study assessed the impact of transient periods of 
improved or worsened INR control on life expectancy and quality-adjusted life years 
(QALYs) among warfarin-treated patients with atrial fibrillation (AF) using both 
metrics. Methods: Warfarin-treated patients with AF, registered in the patient 
record system Journalia during years 1985-2000, were included. Information on all-
cause mortality was collected from the Cause of Death Register. Scenarios where 
patients were assumed to have a transiently altered INR control during 30 days 
were modeled statistically using hazard functions, and the impact on remaining life 
expectancy and QALYs was assessed. Results: When using SDTINR, a 70-year old 
man within the 2.5th worst INR control percentile was estimated to gain 10.8 days of 
life or 0.0168 QALYs from a 30-day improvement in INR control to that of an average 
70-year old man. Correspondingly, 15.5 days of life or 0.0196 QALYs would be lost if a 
70-year old man within the 2.5th best INR control percentile would have an average 
INR control during 30 days. The magnitudes were smaller when TTR was used to 
determine INR control. ConClusions: Even short periods of altered INR control 
is expected to have impact on life expectancy and QALYs among patients with AF.
MeDIcal DevIce & DIaGnostIc research
MD1
coMparInG vIrtual colonoGraphy wIth conventIonal colonoscopy 
for colorectal cancer screenInG: what are the DrIvers of cost-
effectIveness?
Kriza C.1, Emmert M.2, Wahlster P.1, Niederländer C.1, Schaller S.U.1, Kolominsky-Rabas P.L.1
1Centre for Health Technology Assessment (HTA) and Public Health (IZPH), University of 
Erlangen-Nuremberg, Erlangen, Germany, 2School of Business and Economics, Institute of 
Management, University of Erlangen-Nuremberg, Nuremberg, Germany
objeCtives: The majority of recent cost-effectiveness reviews concluded that 
computerized tomographic colonography (CTC) is not a cost-effective Colorectal 
Cancer (CRC) screening strategy yet. The objective of this review is to examine 
cost-effectiveness of CTC versus optical colonoscopy (COL) for CRC screening and 
identify the main drivers influencing cost-effectiveness due to the emergence of 
new research. Methods: A systematic review was conducted for cost-effectiveness 
studies comparing CTC and COL as a screening tool and providing outcomes in 
life-years saved, published between January 2006 and November 2012. The fol-
lowing databases were searched: PubMed, Science Direct, Cochrane Library and 
the York Centre for Reviews and Dissemination databases. The search methodol-
ogy was in line with PRISMA guidelines, including the use of the PICOS review 
system. Results: Nine studies were included in the review. There was consid-
erable heterogeneity in modelling complexity and methodology. Different model 
assumptions and inputs had large effects on resulting cost-effectiveness. The most 
important assumptions that influenced the cost-effectiveness of CTC and COL were 
related to CTC threshold-based reporting of polyps, CTC cost, CTC sensitivity for 
